Alaska Permanent Fund’s BioMarin Pharmaceuticals BMRN Stock Holding History

Alaska Permanent Fund’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$25K	Sell	243 -124	-34%	-$11.6K	﹤0.01%	370
2022 Q3	$31K	Sell	367 -11	-3%	-$979	﹤0.01%	367
2022 Q2	$32K	Sell	378 -205	-35%	-$16.3K	﹤0.01%	366
2022 Q1	$45K	Sell	583 -76	-12%	-$6.36K	﹤0.01%	303
2021 Q4	$58K	Buy	+659	New	+$54.4K	﹤0.01%	296

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Alaska Permanent Fund's BMRN Position: Q4 2022 in Review

Alaska Permanent Fund reduced its BioMarin Pharmaceuticals (BMRN) stake by 34% in Q4 2022, selling an estimated $11.6K and leaving 243 shares worth $25K. The position accounts for ﹤0.01% of the portfolio, ranked #370.

Alaska Permanent Fund first reported a position in BMRN in Q4 2021 and has held it in 5 quarters since. The position peaked at $58K in Q4 2021. 580 funds tracked by Wall St. Rank hold BMRN as of Q4 2022.

Alaska Permanent Fund held 243 shares of BioMarin Pharmaceuticals worth $25K as of Q4 2022.
Alaska Permanent Fund sold 124 BioMarin Pharmaceuticals shares in Q4 2022, an estimated $11.6K.
BioMarin Pharmaceuticals made up ﹤0.01% of Alaska Permanent Fund's portfolio in Q4 2022, its #370 holding.
Alaska Permanent Fund first reported a position in BioMarin Pharmaceuticals in Q4 2021 and has held it in 5 quarters since.
Alaska Permanent Fund's BioMarin Pharmaceuticals position peaked at $58K in Q4 2021.
580 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2022.

Based on Alaska Permanent Fund's 13F filing for Q4 2022, filed 8 Feb 2023.